Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 26c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.40), $0.26 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Delta Air Lines stock climbs on earnings beat and strong guidance